Navigation Links
RheumatologyNetwork Presents RA Findings from ACR Annual Meeting
Date:12/3/2013

NORWALK, Conn., Dec. 3, 2013 /PRNewswire/ -- UBM Medica US announces two new videos on RheumatologyNetwork, the leading online community for rheumatologists,  describing startling findings about rheumatoid arthritis, an autoimmune condition that affects about 1.3 million adults in the United States.

Despite dramatic advances in new drugs for rheumatoid arthritis (RA) treatment, according to research presented at the recent American College of Rheumatology annual meeting in San Diego (and recounted in the videos):

  • Many patients continue to experience considerable pain months after treatment with the new biologic drugs has started, even though their doctors may think that treatment has been successful because inflammation has been reduced
  • Urged by national guidelines to begin treatment for rheumatoid arthritis as soon as possible because the new medications are so successful, some doctors run the risk of initiating treatment for patients who would recover spontaneously.

Research from the Karolinska University Hospital in Sweden, described in the video "Big Flaw in RA Treatment Success Record: Remaining Pain" by Karolinska rheumatologist Jon Lampa, tracked records from more than 8000 RA patients and controls in a Swedish database and found that many continued to have pain three months after beginning treatment.  It's important for doctors to track pain as well as inflammation, he says.

Many rheumatologists refer to a "window of opportunity" during which they can begin to treat RA early enough so that it never becomes severe. In the video  "When Does the RA Window of Opportunity Actually Open" by rheumatologist Ellen Sauar Norli MD of the Martina Hanssens Hospital in Gjettem, Norway, the authors try to define the duration of pain and clinical indicators that optimize the likelihood that joint pain actually represents rheumatoid arthritis and not a more transient problem, before rheumatologists initiate treatment with expensive and potentially dangerous drugs.

About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world.. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections.  Headquartered in New York, UBM Connect brings together UBM's healthcare business, UBM Medica US; UBM Canon's advanced design and manufacturing event, online and print brands; UBM Connect New York's catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico's concrete show.  For more information, visit www.UBMMedicaUS.com.

About UBM plc
UBM plc is a global events-led marketing services and communications company.  We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content.  Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.

For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.

Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
jason.golden@ubm.com


'/>"/>
SOURCE UBM Medica US
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Burzynski Clinic Presents the Results of a Phase II Study of Antineoplastons in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma at the Congress
2. Ventana presents CareGiver remote support at 2013 DreamForce
3. DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
4. Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
5. Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
6. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
7. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
8. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
9. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
10. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
11. Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/28/2017)... Salt Lake City, UT (PRWEB) , ... April 28, 2017 , ... ... that exist in some of their formulas. This begins with the popular ClearLungs Extra ... impacted, they will be changing the formula in the following ways:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to ... of Water, Global Climate Change and Your Health on Voice America sponsored by ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
(Date:4/28/2017)... ... , ... People are starting to accept that hearing aids can be helpful ... stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer ... East region. Côté has 20+ years of experience within the beauty industry, ranging ... with an array of high-end cosmetic brands, retail brands and outlets in Canada ...
Breaking Medicine News(10 mins):